Journal ArticleDOI
Control of clofibrate toxicity in uremic hypertriglyceridemia.
TLDR
The dose of clofibrate administered to hemodialysis patients can be adjusted to avoid toxicity and provide the desired therapeutic effect by monitoring serum CPK and TG levels.Abstract:
A daily dose of 1.5 to 2.0 gm of clofibrate lowers serum triglyceride (TG) levels in patients with normal renal function but causes muscle toxicity and elevated creatine phosphokinase (CPK) levels in patients with long-term renal failure. Plasma clofibrate disappearance is prolonged as much as seven times normal in severely uremic patients. A marked reduction in the standard 14 gm/wk clofibrate dose to a total dose of 1.0 to 1.5 gm/wk effectively lowered serum TG levels (--28%, p less than 0.02) in hypertriglyceridemic hemodialysis patients without toxicity. The serum clofibrate level at this dose was comparable to that in hypertriglyceridemic nonuremic patients receiving 14 gm/wk of clofibrate. The dose of clofibrate administered to hemodialysis patients can be adjusted to avoid toxicity and provide the desired therapeutic effect by monitoring serum CPK and TG levels.read more
Citations
More filters
Book
Drug Prescribing in Renal Failure: Dosing Guidelines for Adults
William M. Bennett,George R. Aronoff,Gail Morrison,Thomas A. Golper,Joseph P. Pulliam,Marsha Wolfson,Irwin Singer +6 more
TL;DR: The data base for rational guidelines to safe, efficacious drug prescribing in adults with renal insufficiency is presented in tabular form in this paper, where recommendations are based on pharmacokinetic variables in normal subjects.
Journal ArticleDOI
Drug glucuronidation in humans.
TL;DR: Factors known to influence the pharmacokinetics of glucuronidated drugs in man, presumably via an effect on specific glucuronosyltransferases, include age, cigarette smoking, diet, certain disease states, coadministered drugs, ethnicity, genetics and hormonal effects.
Journal ArticleDOI
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
Bertram L. Kasiske,Fernando G. Cosio,Judith A. Beto,K. Bolton,Blanche M. Chavers,Richard H. Grimm,Adeera Levin,B. Masri,Rulan S. Parekh,Christoph Wanner,David C. Wheeler,Peter W.F. Wilson +11 more
TL;DR: These guidelines, which are a modified version of the K/DOQI dyslipidemia guidelines, were developed to aid clinicians in the management of dyslipidemias in kidney transplant patients and are supported mainly by data from studies in the general population but there is an urgent need for additional studies in CKD and in transplant patients.
Journal ArticleDOI
Management of Dyslipidemia in NIDDM
Abhimanyu Garg,Scott M. Grundy +1 more
TL;DR: The National Cholesterol Education Program recently issued guidelines for treatment of hyperlipidemia in adults including diabetic patients as discussed by the authors, which suggest that certain modifications in these guidelines be made to meet specific needs of diabetic patients.
Journal ArticleDOI
Cardiovascular complications in renal failure.
TL;DR: The presence of resting electrocardiographic abnormalities caused by hypertension or conduction defects makes it difficult to accurately diagnosis coronary artery disease in ESRD populations by noninvasive methods, including exercise testing and thallium scintigraphy with or without the use of dipyridamole.
References
More filters
Journal ArticleDOI
Accelerated Atherosclerosis in Prolonged Maintenance Hemodialysis
TL;DR: The survival experience of 39 patients receiving long-term regular hemodialysis in Seattle since 1960 was studied with particular reference to mortality and morbidity from arteriosclerotic...
Journal ArticleDOI
Hyperlipidemia in Coronary Heart Disease II. GENETIC ANALYSIS OF LIPID LEVELS IN 176 FAMILIES AND DELINEATION OF A NEW INHERITED DISORDER, COMBINED HYPERLIPIDEMIA
TL;DR: The combined disorder was shown to be genetically distinct from familial hypercholesterolemia and familial hypertriglyceridemia for the following reasons: the distribution pattern of cholesterol and triglyceride levels in relatives of probands was unique.
Journal ArticleDOI
Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction
TL;DR: The identification of hyperlipidemic survivors of myocardial infarction provided a unique source of probands for family studies designed to disclose the genetic origin ofhyperlipidemia in coronary heart disease.
Journal ArticleDOI
Hypertriglyceridemia. A metabolic consequence of chronic renal failure.
Journal ArticleDOI
Myocardial infarction in the familial forms of hypertriglyceridemia.
John D. Brunzell,John D. Brunzell,Helmut G. Schrott,Helmut G. Schrott,Arno G. Motulsky,Arno G. Motulsky,Edwin L. Bierman,Edwin L. Bierman +7 more
TL;DR: The frequency of myocardial infarction in living hyperlipedemic relatives with familial hypertriglyceridemia was similar to the frequency among normolipidemic relatives (4.5%) or among spouse controls (5.2%).